We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Controversies in Neurology |

Intravenous Immunoglobulin Treatment in Neurologic Disorders

Vladimir Hachinski, MD, FRCPC, DSc
Arch Neurol. 1999;56(8):1032. doi:10.1001/archneur.56.8.1032.
Text Size: A A A
Published online


A THERAPY used in a variety of disorders is bound to yield varying results. Sorensen thinks that intravenous immunoglobulin (IVIG) treatment is effective in Guillain-Barré syndrome. Karussis and Abramsky consider it an inferior choice that should be used only when plasmapheresis is contraindicated or unavailable. Sorensen thinks that IVIG should be used in chronic inflammatory demyelinating polyneuropathy. Karussis and Abramsky acknowledge this, but point out that some patients do not respond to IVIG, that the therapeutic effect fades in others, and that steroids remain the treatment-of-choice followed by plasmapheresis. All contributors agree that there is a role for IVIG in dermatomyositis and multifocal motor neuropathy. Its use in myasthenia gravis and Lambert-Eaton syndrome is less well founded, speculative in multiple sclerosis, and hazardous in neuromyotonia.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles
[Not Available]. Rev Med Suisse 2016;12(523):1204-5.